In the Literature

  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Enzalutamide Superior to Bicalutamide in Patients with Prostate Cancer
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Ixazomib Extends Progression-Free Survival in Multiple Myeloma
  • Pembrolizumab Shows Potential Antitumor Activity in Advanced Gastric Cancer
  • ASCO Endorses Canadian Clinical Practice Guideline on Active Surveillance for Localized Prostate Cancer
  • Delayed Relapses After Anti–PD-1 Therapy Linked to Mutation in Patients with Melanoma
  • ASCO Issues Guidelines for Developing Clinical Pathways That Promote Value-Based Care
  • Second Cancer Risk Is High After Hodgkin Lymphoma
  • Cancer Screening May Not Save Lives, a New Analysis Suggests
  • ASCO Issues Guidelines for Developing Clinical Pathways That Promote Value-Based Care
  • Second Cancer Risk Is High After Hodgkin Lymphoma
  • Cancer Screening May Not Save Lives, a New Analysis Suggests s
Hepatocellular carcinoma is the second most common cause of cancer-related death and occurs most often in patients with cirrhosis. Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and angiogenesis, and is overexpressed in patients with hepatocellular carcinoma.

Results 1 - 8 of 8